A rising star in BMS’s finance department, Tatiana Simonelli, SVP, finance commercialization at BMS discusses her path to senior leadership, and how talent diversity can boost business results.

As buzzy development areas buckle down to face the realities of strict regulations, financial demands, and specific unmet needs, the language leaders use to describe their efforts can help, or hurt.

Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.

Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.

New and improved ways of measuring disease symptoms and responses to therapy must overcome established forms of measurement used for regulatory approval. 

Ahmed Hamdy and Raquel Izumi are putting the lessons, hard knocks, and experiential wisdom they have gained over a decade in biotech to work at Vincerx.

I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.

With a new manufacturing plant opening in Virgina, Civica is poised to move into new product areas, including affordable insulin.

Bringing different perspectives together is important when debating industry policies, but the middle ground can still be allusive.